Published in Am J Clin Pathol on January 01, 1998
Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol (2004) 4.03
Fusarium infections in immunocompromised patients. Clin Microbiol Rev (2007) 3.44
Current perspectives on ophthalmic mycoses. Clin Microbiol Rev (2003) 3.18
Fusarium oxysporum as a multihost model for the genetic dissection of fungal virulence in plants and mammals. Infect Immun (2004) 1.67
In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother (2004) 1.44
Microscopic evaluation, molecular identification, antifungal susceptibility, and clinical outcomes in fusarium, Aspergillus and, dematiaceous keratitis. Biomed Res Int (2013) 1.13
Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) (2011) 0.97
Paecilomyces variotii as an Emergent Pathogenic Agent of Pneumonia. Case Rep Infect Dis (2013) 0.94
Fatal endocarditis in a neonate caused by the dematiaceous fungus Phialemonium obovatum: case report and review of the literature. J Clin Microbiol (2002) 0.93
Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion (2015) 0.92
Morphologic identification of mycelial pathogens in tissue sections. A caveat. Am J Clin Pathol (1998) 0.87
Invasive infection with Fusarium chlamydosporum in a patient with aplastic anemia. J Clin Microbiol (1998) 0.87
Purpureocillium lilacinum as a cause of cavitary pulmonary disease: a new clinical presentation and observations on atypical morphologic characteristics of the isolate. J Clin Microbiol (2012) 0.85
Acremonium Pneumonia: Case Report and Literature Review. Tanaffos (2015) 0.82
A Rare Case of Fungal Maxillary Sinusitis due to Paecilomyces lilacinus in an Immunocompetent Host, Presenting as a Subcutaneous Swelling. J Lab Physicians (2011) 0.81
Disseminated mycosis in veiled chameleons (Chamaeleo calyptratus) caused by Chamaeleomyces granulomatis, a new fungus related to Paecilomyces viridis. J Clin Microbiol (2010) 0.80
Adventitious sporulation in Fusarium keratitis. Graefes Arch Clin Exp Ophthalmol (2011) 0.80
Localized cutaneous hyalohyphomycosis caused by a Fusarium species infection in a renal transplant patient. J Clin Microbiol (2003) 0.79
Fatal case of Trichoderma harzianum infection in a renal transplant recipient. J Clin Microbiol (1999) 0.79
Pseudo-outbreak of Lecanicillium and Acremonium species in orthopedic surgery patients. J Clin Microbiol (2012) 0.77
Uncommon opportunistic fungal infections of oral cavity: A review. J Oral Maxillofac Pathol (2014) 0.75
Successful Treatment of Disseminated Fusariosis with the Combination of Voriconazole and Liposomal Amphotericin B. Turk J Haematol (2016) 0.75
Fusarium solani infection in a kidney transplant recipient. Indian J Nephrol (2014) 0.75
A Rare Case of Nasal Septal Perforation Due to Purpureocillium lilacinum: Case Report and Review. Indian J Otolaryngol Head Neck Surg (2012) 0.75
Peritonitis due to Thermoascus taitungiacus (Anamorph Paecilomyces taitungiacus). J Clin Microbiol (2001) 0.75
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics (1985) 5.30
Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol (1993) 5.14
Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol (1980) 4.28
Cryptococcus neoformans mating and virulence are regulated by the G-protein alpha subunit GPA1 and cAMP. Genes Dev (1997) 4.28
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis (2001) 4.01
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest (1985) 3.98
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother (1993) 3.79
Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med (1996) 3.76
Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. J Clin Invest (1988) 3.69
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother (1986) 3.38
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother (1996) 3.20
Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol Cell Biol (2001) 3.11
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis (1998) 3.09
NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol (1987) 3.06
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest (1990) 2.91
Infection due to Actinobacillus actinomycetemcomitans: 15 cases and review. Rev Infect Dis (1989) 2.89
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother (1997) 2.76
RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. Mol Microbiol (2000) 2.30
Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis (2006) 2.17
The new fungal opportunists are coming. Clin Infect Dis (1996) 2.10
Cryptococcemia. Medicine (Baltimore) (1983) 2.10
Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. J Immunol (1986) 2.06
The G-protein beta subunit GPB1 is required for mating and haploid fruiting in Cryptococcus neoformans. Mol Cell Biol (2000) 2.03
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother (1985) 2.02
Identification of the MATa mating-type locus of Cryptococcus neoformans reveals a serotype A MATa strain thought to have been extinct. Proc Natl Acad Sci U S A (2000) 1.96
Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J Infect Dis (1987) 1.85
Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob Agents Chemother (1985) 1.78
Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J (2000) 1.76
The STE12alpha homolog is required for haploid filamentation but largely dispensable for mating and virulence in Cryptococcus neoformans. Genetics (1999) 1.75
Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest (2001) 1.74
Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci U S A (1994) 1.72
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev (2001) 1.72
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.66
A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol (1999) 1.65
Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol Cell Biol (1999) 1.64
Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs (1997) 1.63
Isolation, culture, and characterization of endothelial cells from Schlemm's canal. Invest Ophthalmol Vis Sci (1998) 1.59
Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. J Infect Dis (1982) 1.58
Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med (1983) 1.56
Dominant selection system for use in Cryptococcus neoformans. J Med Vet Mycol (1997) 1.54
Community respiratory viral infection in adult lung transplant recipients. Chest (1998) 1.53
Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl (2000) 1.53
Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol (1985) 1.52
Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis (1999) 1.51
Fungal meningitis. Semin Neurol (2000) 1.50
Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. Eukaryot Cell (2003) 1.49
A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol (2000) 1.49
Two cyclophilin A homologs with shared and distinct functions important for growth and virulence of Cryptococcus neoformans. EMBO Rep (2001) 1.46
Disseminated zygomycosis: report of four cases and review. Rev Infect Dis (1989) 1.45
Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother (2000) 1.42
Diagnostic yield of bronchoscopies after isolated lung transplantation. Chest (1996) 1.42
Signal transduction pathways regulating differentiation and pathogenicity of Cryptococcus neoformans. Fungal Genet Biol (1998) 1.41
Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemother (2001) 1.37
Trichodysplasia spinulosa--a newly described folliculocentric viral infection in an immunocompromised host. J Investig Dermatol Symp Proc (1999) 1.33
Enhanced green fluorescent protein as a marker for localizing murine cytomegalovirus in acute and latent infection. J Virol Methods (2000) 1.33
Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis (1985) 1.31
Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents. Antimicrob Agents Chemother (1998) 1.29
Influence of agglutinating antibody in experimental cryptococcal meningitis. Br J Exp Pathol (1981) 1.29
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2012) 1.28
Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother (1987) 1.27
Diguanidino and "reversed" diamidino 2,5-diarylfurans as antimicrobial agents. J Med Chem (2001) 1.25
Scedosporium species infections and treatments. J Chemother (2003) 1.23
Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect Immun (1990) 1.23
Cryptococcus neoformans differential gene expression detected in vitro and in vivo with green fluorescent protein. Infect Immun (1999) 1.22
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev (1999) 1.21
Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob Agents Chemother (1999) 1.21
The actin gene from Cryptococcus neoformans: structure and phylogenetic analysis. J Med Vet Mycol (1996) 1.21
Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis (2008) 1.20
P-Selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver. Hepatology (1999) 1.20
Effects of cyclosporine in experimental cryptococcal meningitis. Infect Immun (1985) 1.19
Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest (2000) 1.18
Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Genomics (1999) 1.17
Identification and characterization of an SKN7 homologue in Cryptococcus neoformans. Infect Immun (2005) 1.16
Chronic aspiration of gastric fluid induces the development of obliterative bronchiolitis in rat lung transplants. Am J Transplant (2008) 1.15
Identification and characterization of the Cryptococcus neoformans phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity. Mol Microbiol (2001) 1.15
Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target. Genetics (1999) 1.15
Fusarium infection in burned patients. Am J Clin Pathol (1981) 1.13
Macrophage-mediated fungistasis: requirement for a macromolecular component in serum. J Immunol (1986) 1.12
The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J Antimicrob Chemother (1990) 1.12
Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother (2000) 1.12
Fungal scleritis after cataract surgery. Successful outcome using itraconazole. Cornea (1992) 1.11
The Cryptococcus neoformans genome sequencing project. Mycopathologia (1999) 1.10
Laparoscopic antireflux surgery in the lung transplant population. Surg Endosc (2002) 1.07
In vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles. Antimicrob Agents Chemother (1998) 1.06
Fatal, disseminated Acremonium strictum infection in a neutropenic host. J Clin Microbiol (1996) 1.03
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother (2012) 1.02
Comparison of cotrimoxazole, ampicillin, and chloramphenicol in treatment of experimental Haemophilus influenzae type B meningitis. Antimicrob Agents Chemother (1980) 1.02
Biochemical role of the Cryptococcus neoformans ADE2 protein in fungal de novo purine biosynthesis. Arch Biochem Biophys (1998) 1.01
Fatal Apophysomyces elegans infection transmitted by deceased donor renal allografts. Am J Transplant (2010) 1.00
Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) (1996) 1.00
Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS (1996) 1.00